Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ONC Capital
Calgary, Alberta, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Pelareorep has shown promising results in randomized Phase 2 studies in metastatic breast cancer, Phase 1/2 studies in pancreatic cancer, and synergies with approved oncology treatments including Keytruda and Tecentriq. Advancing to registrational studies in metastatic breast cancer (HR+/HER2-), pancreatic ductal adenocarcinoma, and other solid tumors.[1][2][3][6]
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapy
- Industry
- Biotech
02
Partnerships
Merck (Keytruda combination)Roche (Tecentriq combination)Merck KGaAPfizer Inc.Adlai Nortye
Beyond the preview
Go deeper on ONC Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONC Capital.